Investors' pessimism about Zhejiang Starry Pharmaceutical's ...
Investors' pessimism about Zhejiang Starry Pharmaceutical's revenue prospects and its lower forecasted growth than the wider industry could be causing its low P/S ratio. These conditions may continue to hinder the share price.
Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3235Followers
0Following
8000Visitors
Follow